RoActemra 162 mg solution for injection in pre-filled syringe. clinical trials
4 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic exploratory (Phase II)
French prospective open label phase II randomized non-comparative study of SC tocilizumab associated with IV pulse steroid versus IV pulse steroid alone for the treatment of acute anterior ischemic optic neuropathy associated with giant cell arteritis. (TOCIAION)
This study looks at a new way to treat sudden vision loss from a condition called giant cell arteritis (GCA). It compares standard treatment with a new drug, tocilizumab, to see if the new drug can help improve eyesight more effectively.
For: Acute Anterior Ischemic Optic Neuropathy associated with Giant Cell Arteritis in Horton's DiseaseFrance - Ongoing, recruitingTherapeutic use (Phase IV)
ABATACEPT VERSUS TOCILIZUMAB BY SUBCUTANEOUS ADMINISTRATION FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN TARGETED TREATMENT INADEQUATE RESPONDER PATIENTS: A RANDOMIZED, OPENLABELED, SUPERIORITY TRIAL. -SUNSTAR-
This study compares two common medicines, Orencia and RoActemra, for adults with rheumatoid arthritis whose current treatments aren't working well enough. We want to see which one works better at reducing disease activity over six months.
For: Adults patients suffering from rheumatoid arthritis and in adequate response to one or two targeted treatments.France - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A multicentre clinical trial evaluating the safety and efficacy of the combination of nintedanib and tocilizumab compared to standard treatment in patients with systemic sclerosis and interstitial lung disease. Analysis with theranostic approach and assessment of cytokine activity, markers of inflammation and pulmonary fibrosis using computed tomography, positron emission tomography, and metabolome and transcriptome studies in selected patients. NINTOC-TU study
This study looks at new ways to treat a specific lung problem called interstitial lung disease (ILD) that can happen with a condition called systemic sclerosis. It compares a new combination of medicines with standard treatment to see if it can help improve breathing and reduce symptoms.
For: systemic sclerosis with interstitial lung disease (ILD) in the course of the diseasePoland - AuthorisedTherapeutic use (Phase IV)
A multicenter, randomized, open-label, blinded-assessor, phase 4 study in patients with early rheumatoid arthritis to compare active conventional therapy versus three biologic treatments, and two de-escalation strategies in patients who respond to treatment.
This study looks at different ways to treat early rheumatoid arthritis, comparing standard treatments with newer biologic medicines. It also explores if medicine doses can be lowered for people who are getting better, aiming to find the most effective and safe long-term approaches.
For: Rheumatoid ArthritisIceland · Denmark · Norway